ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

British Journal of Dermatology

British Journal of Dermatology

Volume 126 Issue s39, Pages 8 - 13

Published Online: 29 Jul 2006

Journal compilation © 2010 British Association of Dermatologists



< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: PDF (Size: 2075K)  | Related Articles | Citation Tracking

Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers
J.M. KOVARIK 1 , S. KIRKESSELI, *H. HUMBERT, *P. GRASS 1 K. KUTZ 1
  1 Department of Human Pharmacology, Sandoz Pharma Ltd, Basel, Switzerland   *Pharmaceutical Research Center, STELL Hospital, Sandoz Laboratories, Rueil-Malmaison, France
Correspondence to  Dr J.M.Kovarik, Department of Human Pharmacology, Sandoz Pharma Ltd, Lichtstrasse 35, CH-4002 Basel, Switzerland.
Copyright 1992 British Association of Dermatologists

ABSTRACT

AbstractReferences

The dose-dependency of the pharmacokinetic parameters of terbinafine and its N-demethyl derivative was investigated in a randomized four-way crossover study in healthy volunteers following single oral administrations of 125, 250, 500 and 750 mg of terbinafine. Plasma concentrations of terbinafine and its metabolite were measured by a validated high-performance liquid chromatography (HPLC) method using ultraviolet detection. Concentration data were fitted to a two-compartment model. The relationship between Cmax or the area under the concentration curve (AUC) and the terbinafine dose was analysed by classical linear regression. Terbinafine disposition parameters were dose-independent, with the exception of Tmax and t1/2x, which were prolonged with the 500- and 750-mg doses. The terbinafine Cmax and AUC, however, were linear and dose-proportional over the entire dose range. The N-demethylated metabolite appeared in plasma at the same time as terbinafine and showed similar prolongations in Tmax and t1/2x with the 500- and 750-mg doses. In addition, the Cmax deviated from proportionality at these doses, giving values 22% lower than projected, while the AUC was linear and dose-proportional over the whole range of doses. The slight disproportionality in the dispositions of terbinafine and its N-demethyl metabolite at 500 and 750 mg are not expected to be clinically significant.


DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1365-2133.1992.tb00002.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Sign Up Now
Sign Up Now
Sign Up Now
Wiley Medical Twitter